America Yuva Biomed

America Yuva Biomed is a clinical-stage biotechnology company focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer. The company utilizes its proprietary 4SCAR platform, which features fourth-generation CAR constructs incorporating safety-switch technologies like inducible caspase-9 to enhance control over T-cell activity and minimize toxicity. Its pipeline includes multiple clinical-stage programs targeting antigens such as CD19, CD123, GD2, and BCMA for the treatment of various hematologic malignancies and solid tumors. Headquartered in Beijing with significant operations in Shenzhen, the company collaborates closely with the Shenzhen Geno-Immune Medical Institute and leading clinical centers in China to advance its immunotherapy candidates. America Yuva Biomed aims to provide effective treatment options for patients with relapsed or refractory cancers who have failed standard therapies.